Zimmer Biomet (NYSE:ZBH) Given New $118.00 Price Target at Stifel Nicolaus
Stifel Nicolaus raised its price target for Zimmer Biomet (NYSE:ZBH) from $115.00 to $118.00, maintaining a "buy" rating. This new target suggests a potential upside of 17.47% from the previous close. Other analysts have also increased their price targets, with an average target of $113.16. Zimmer Biomet's stock is currently trading at $100.45, with a market cap of $19.90 billion. The company reported a quarterly EPS of $2.07, exceeding estimates, and has set FY 2025 guidance at 8.100-8.300 EPS.
Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price objective boosted by analysts at Stifel Nicolaus from $115.00 to $118.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the medical equipment provider's stock. Stifel Nicolaus' price objective points to a potential upside of 17.47% from the company's previous close.
- Intuitive Surgical Leads the Pack in Robotic Surgery Innovation
A number of other research analysts also recently issued reports on the company. Raymond James Financial boosted their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Royal Bank Of Canada boosted their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research note on Thursday. Rothschild Redb raised Zimmer Biomet to a "strong-buy" rating in a research report on Thursday. Finally, Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a research report on Thursday. They issued a "buy" rating and a $130.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $113.16.
Get Zimmer Biomet alerts:
Read Our Latest Research Report on Zimmer Biomet
Zimmer Biomet Trading Up 0.2%
- 2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead
ZBH traded up $0.24 during midday trading on Friday, hitting $100.45. 288,498 shares of the company were exchanged, compared to its average volume of 1,964,456. The firm has a market capitalization of $19.90 billion, a P/E ratio of 24.44, a P/E/G ratio of 2.30 and a beta of 0.68. Zimmer Biomet has a 1-year low of $89.22 and a 1-year high of $114.72. The firm's 50 day moving average price is $99.93 and its 200-day moving average price is $99.46. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.
Insider Activity
- Boston Scientific: Why This MedTech Giant Isn’t Slowing Down
In other news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company's stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.39% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Zimmer Biomet
Several institutional investors have recently modified their holdings of ZBH. Garde Capital Inc. bought a new position in shares of Zimmer Biomet in the first quarter valued at approximately $29,000. Menard Financial Group LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at approximately $30,000. Washington Trust Advisors Inc. purchased a new position in Zimmer Biomet in the first quarter valued at approximately $30,000. Columbia River Financial Group LLC purchased a new position in Zimmer Biomet in the first quarter valued at approximately $30,000. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. 88.89% of the stock is owned by institutional investors.
About Zimmer Biomet
(Get Free Report)Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Recommended Stories
- Five stocks we like better than Zimmer Biomet
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Reasons Amazon Could Be at an All-Time High by October
- Value Investing: Is it a Good Strategy in 2022? Hint: Always
- Workday Rising… To Fresh Record High Stock Prices
- Short Selling - The Pros and Cons
- McDonald’s: New All-Time Highs Are Inevitable
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Zimmer Biomet Right Now?
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
